Results 91 to 100 of about 2,048,259 (212)

Descriptive statistics of ABCB7 expression levels in CD34⁺ cells according to FAB group, in CD34⁺ cells according to percentage of bone marrow ring sideroblasts, and in cultured erythroblasts at day 7.

, 2013
Descriptive statistics of ABCB7 expression levels in CD34+ cells according to FAB group, in CD34+ cells according to percentage of bone marrow ring sideroblasts, and in cultured erythroblasts at day 7.
Jacqueline Boultwood (89560), Martin Jädersten (89569), David Bowen (89572), Carrie Fidler (89564), Luca Malcovati (89567), Helen Cattan (89565), Sally Killick (89570), Mario Cazzola (89574), Beena Pushkaran (89563), Andrea Pellagatti (89561), Tim J. Littlewood (89566), Aristoteles Giagounidis (89571), Matteo G. Della Porta (89568), Eva Hellström-Lindberg (89573), James S. Wainscoat (89575), Maryam Nikpour (89562)   +15 more
core   +1 more source

TGFβ-activated kinase-1 knockdown in hematopoietic stem-progenitor cells causes PANoptosis and myelodysplastic syndrome-like disease in mice

Haematologica
Mutant SF3B1 (SF3B1mut) in hematopoietic stem/progenitor cells (HSPCs) primarily affects erythropoiesis, resulting in myelodysplastic syndromes (MDS) with refractory macrocytic anemia and ring sideroblasts.
Lei Zhang, Wenyan Li, Rohit Thalla, Rongyao Ma, Ryan Mack, Ameet R. Kini, Austin Runde, Patrick A. Hagen, Kevin Barton, Jorgena Kosti-Schwartz, Peter Breslin, Hong-Long Ji, Jiwang Zhang   +12 more
doaj   +1 more source

Severe Macrocytic Anemia Associated With a Novel ALAS2 Mutation: A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT X‐linked sideroblastic anemia (XLSA), caused by pathogenic variants in ALAS2, typically presents as microcytic anemia in males. However, heterozygous females occasionally exhibit an atypical macrocytic phenotype, often leading to diagnostic ambiguity and confusion with nutritional anemias or myelodysplastic syndromes.
Haodong Cai, Kefeng Shen, Jin Wang, Jia Gu, Meilan Zhang, Min Xiao   +5 more
wiley   +1 more source

LONG-TERM EFFECTIVENESS AND SAFETY OF LUSPATERCEPT FOR ANEMIA TREATMENT IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES: A SYSTEMATIC REVIEW AND META-ANALYSIS

Hematology, Transfusion and Cell Therapy
Introduction: Erythropoiesis-stimulating agents (ESA) are the primary treatment for anemia in most patients with low to moderate-risk myelodysplastic syndromes.
DVS Cavalcante, IQC Neto, IO Môro, RGO Galvão, JF Abreu, AM Cavalcante, MCFLC Freitas, V Lopes, BX Mendes, FD Xavier   +9 more
doaj   +1 more source

Ruxolitinib Pharmacokinetics and Exposure–Toxicity Relationship in Hematologic Malignancies and Immune‐Mediated Diseases: A Prospective Observational Study

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 753-761, September 2026.
Ruxolitinib pharmacokinetics (PK) has been characterized in clinical trials but remains poorly documented in real‐world practice. This project aimed to investigate ruxolitinib PK in routine clinical practice, identify factors driving its variability, and explore exposure–response relationships to assess the potential role of therapeutic drug monitoring.
Jérémie Tachet, Sara C. Meyer, Francesco Grandoni, Emmanuel Haefliger, Monika Nagy‐Hulliger, Jörg P. Halter, Jakob R. Passweg, David Haefliger, Carine Bardinet, Laurent A. Decosterd, Monia Guidi, François R. Girardin   +11 more
wiley   +1 more source

Mesangial sclerosing glomerulopathy following luspatercept treatment – a case report

BMC Nephrology
Luspatercept is a recombinant fusion protein that enhances late-stage erythropoiesis by inhibiting select transforming growth factor β (TGFβ) superfamily ligands.
Stanislas Bataille, Laurent Daniel, Julia Torrents, Vincent Javaugue, Philippe Giaime, Cécile Castoldi, Amélie-Jade Poiré, Stéphane Burtey   +7 more
doaj   +1 more source

Inherited microcytic anemias due to disorders of iron and heme metabolism: An updated clinical review

HemaSphere, Volume 10, Issue 9, September 2026.
Abstract Microcytic anemia is among the most common hematological abnormalities in clinical practice and is usually attributable to iron deficiency, thalassemia traits, or anemia of inflammation. A small but clinically important subset of patients, however, has inherited disorders of iron metabolism or heme synthesis presenting with persistent ...
Alexandros Makis, Ioanna Saougou, Eleftheria Hatzimichael   +2 more
wiley   +1 more source

Causes and Pathophysiology of Acquired Sideroblastic Anemia

, 2022
The sideroblastic anemias are a heterogeneous group of inherited and acquired disorders characterized by anemia and the presence of ring sideroblasts in the bone marrow.
Leonor Arenillas, Rodriguez-Sevilla, Juan Jose, Juan Jose Rodriguez-Sevilla, Xavier Calvo, Calvo, Xavier, Arenillas, Leonor, Arenillas Rocha, Leonor   +6 more
core   +1 more source

Congenital sideroblastic anaemia

Journal of Clinical and Scientific Research
A 24-year-old male born out of a consanguineous marriage presented with a long-standing history of microcytic anaemia. He was treated elsewhere for the same with haematinics and packed red cell transfusions and had not shown improvement.
Kavya Sree Velchuri, Mallikarjuna Shetty, Adiraju Krishna Prasad, Purna Surya Kiran Pentakota   +3 more
doaj   +1 more source

Basophilic Stippling and Ringed Sideroblasts Revealing Hidden Lead Poisoning in Refractory Microcytic Anemia

eJHaem, Volume 7, Issue 5, October 2026.
Huishuang Gao, Miaoke Dai, Jing Zhou, Xiang Li, Yongzhong Ning   +4 more
wiley   +1 more source